

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **January 31, 2024**

**NEXGEL, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction  
of incorporation)

**001-41173**

(Commission  
File Number)

**26-4042544**

(IRS Employer  
Identification No.)

**2150 Cabot Boulevard West, Suite B  
Langhorne, Pennsylvania**

(Address of principal executive offices)

**19067**

(Zip Code)

Registrant's telephone number, including area code: **(215) 702-8550**

(Former name or former address, if changed since last report)

**Not Applicable**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class               | Trading Symbol(s) | Name of each exchange on which registered |
|-----------------------------------|-------------------|---|
| Common Stock, par value \$0.001   | NXGL              | The Nasdaq Capital Market LLC             |
| Warrants to Purchase Common Stock | NXGLW             | The Nasdaq Capital Market LLC             |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure.**

On January 31, 2024, NexGel, Inc. began utilizing a new investor presentation, a copy of which is attached hereto as Exhibit 99.1.

The information in Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "*Exchange Act*"), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

| Exhibit<br>No. | Description   |
|----------------|---|
| 99.1           | <a href="#">NexGel, Inc. Investor Presentation, dated January 2024.</a> |
| 104            | Cover Page Interactive Data File (formatted as Inline XBRL)             |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 31, 2024

**NEXGEL, INC.**

By: /s/ Adam Levy  
Adam Levy  
Chief Executive Officer

---



# Investor Presentation

January 2024



NASDAQ: NXGL

## Forward-Looking Statement

This presentation contains certain forward-looking statements, including those relating to the Company's product development, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature.

Additional written and oral forward-looking statements may be made by the Company from time to time in filings with the Securities and Exchange Commission (SEC) or otherwise.

The Private Securities Litigation Reform Act of 1995 provides a safe-harbor for forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms.

These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the SEC.

Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this presentation. Except as otherwise required by law, the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.



NASDAQ: NXGL

# NEXGEL - Who We Are and What We Do

After two decades of creating custom hydrogel solutions for large medical device companies, NEXGEL has expanded its scope of business to include the development of our own patented medical devices, drug delivery systems, over-the-counter (OTC) healthcare consumer products, beauty and cosmetic items and nutritional supplements. Additionally, we've invested in in-house converting and packaging capabilities to ensure a comprehensive approach to meeting the evolving needs of our customers. These strategic expansions reflect our dedication to pioneering advancements across various domains, delivering great value to our customers and stakeholders.



NASDAQ: NXGL

## Competitive Advantage: 1 of 2 State-of-the-Art Manufacturing Facilities in NA

*Medical grade technology and facility, providing gels to multi-national device companies for over 20 years with sufficient capacity to fulfill consumer and healthcare segments*

1 of 2 manufacturing facilities in North America that can produce state-of-the-art hydrogel transdermal products  
– successfully used 200+ different active ingredient combinations to date

16,500-square-ft GMP  
13,500-square-ft manufacturing space

3,000-square-ft office space

>1.4 Billion square inches of product per year is total capacity

Sufficient capacity across healthcare and consumer divisions

Electron Beam Accelerator eliminates the need for harmful chemicals in hydrogel production

High barrier to entry for new facilities (2+ yrs to go live)

Stringent compliance requirements

Technical expertise needed to operate



NASDAQ: NXGL

# Hydrogels for Consumer and Medical Applications

- Electron beam technology eliminates the need for harmful chemicals in cross-linking, which, along with our paraben-free formulation, makes our patches the only option for many medical device applications and preferred among consumers
- Gentle formulation & strong adhesion properties eliminates many problems with existing transdermal devices & dermal interfaces such as:
  - Deterioration of skin integrity
  - Skin allergies
  - Skin irritation
  - Discomfort
  - Skin tears
  - Removal of dermis
  - Pain

*All of these contribute to increased risk of infection and overall patient dissatisfaction*

# Multiple Shots on Goal for Growth



# Multiple Aspirational Medical Device Opportunities

Addressing the importance of skin integrity and overall skincare with a medical device



NASDAQ: NXGL

## Medical Device Applications – Drug Delivery, NEXDrape & NEXDerm


**Drug Delivery** – Potential for drug delivery through unique hydrogels

**NEXDrape** – A “skin friendly” solution for the surgical drape 510(k) market

- Disrupting the rapidly growing surgical drape industry by providing consistent adhesion; greater skin integrity; comfortable removal post surgery; decreased skin irritation
- Worldwide patents filed
- In early-stage discussions with multiple companies to co-develop and/or market NEXDrape

**NEXDerm** – For central lines and IVs

- Offers anti-microbial properties, is repositionable, gentle to the skin, pain-free removal, and helps prevent infection
- Potential future applications in the medical device space:
  - negative pressure
  - colostomy bags
  - skin scaffolds



Leading Brand



NASDAQ: NXGL

---

## Amblyopia Treatment

- Amblyopia - type of poor vision that typically occurs in one eye, but can occur in both eyes (also referred to as lazy eye)
- Most common cause of visual impairment in childhood & affects approx. 2 to 3 children out of every 100
- Global Amblyopia market expected to reach over \$6 billion by 2027
- Current standard of care are patches placed directly on the skin covering the eye, difficult to adjust and remove, pulling at and irritating the skin
- NEXGEL's hydrogel patch is significantly gentler on the skin and manufactured without the use of harsh chemicals or painful adhesives
- Launched directly to Ophthalmologists and Optometrists in 2H 2023 to gather patient feedback- Potential widescale launch in 1H 2024 to include DTC

---

## Consumer Health & Beauty

Bringing proven medical-grade technology to OTC and B&C for the first time through many new consumer products & applications

## Multiple Low-Risk Revenue Paths for Consumer Segment

Research  
Development /  
Custom Label

White  
Label

DTC /  
E-Commerce  
Proprietary  
Brands



NOW PARABEN-FREE



NASDAQ: NXGL

11

## Custom & White Label Strategy

*NEXGEL leverages platform to supply OTC brands with unique, gentle hydrogel-based products*

- All UV cured hydrogel patches contain AMP-acrylates/vinyl Isodecanoate crosspolymer, Toluene, and Vinyl acetate, or similar chemicals, which are non-starters for the Beauty & Cosmetics industry, as are parabens which we have removed
- Customers pay a development fee to create custom products. NEXGEL has no financial risk in the product's success or failure
- White label projects increase awareness that NEXGEL is a consumer-friendly and reliable supplier of customizable patches
- After extensive due diligence, signed partnership agreements with three multi-billion companies: Haleon, AbbVie and STADA



NASDAQ: NXGL

12



## Supply Agreement with AbbVie (NYSE: ABBV)

*CG Converting and Packaging is exclusive supplier of gel pads to be used with AbbVie's Rapid Acoustic Pulse device for the improvement in the appearance of cellulite*

- Allergan Aesthetics, acquired by AbbVie, purchased Soliton, the owner of the Resonic technology, for \$550 million in December 2021
- Leveraging NEXGEL's proprietary hydrogel technology, the gel pads are an important component and must be used FOR ALL body contouring device treatments
- It is expected the Resonic technology will be rolled out by the middle of 2024



**THE WALL STREET JOURNAL.**  
**Allergan Aesthetics**  
**Completes \$550M**  
**Acquisition of Soliton**  
December 22, 2021



NASDAQ: NXGL

## Partnership with STADA Arzneimittel AG

*Signed December 2023, partnership with European leader in consumer health supports expansion of NEXGEL OTC product portfolio*

- Mutually beneficial partnership to distribute and commercialize STADA consumer health OTC products in North America in 2024.
- STADA already focuses on consumer healthcare products, generics and specialty pharm, selling products in approximately 120 countries across the world and this partnership will provide a path into North America.
- In 2022, STADA generated revenue of EUR 3.8 billion and EBITDA of EUR 885 million.



NASDAQ: NXGL

## Joint Venture with C.G. Laboratories

50-50 ownership in converting and packaging business in Granbury, Texas

- CG Labs current converting and packaging division is one of NEXGEL's largest customers for many years, revenue generating and already profitable
- Transaction immediately increases converting and packaging capacity, improves margins and streamlines supply chain
- Significant synergies, allowing for onboarding of potential finished goods customers as well as combined marketing and customer outreach
- Deal completed in March 2023 for \$500,000 in cash, committed over time
- Already contributed materially to top line growth during Q2 of 2023 and is accretive to earnings

## Proprietary Branded Products

Rapid growth since launch in Q4-2020

- Medagel brand selling 11 SKUs on Amazon.com addressing:
  - Migraine Relief
  - Sports & Sports Related Applications
  - General Podiatry
  - Burn / Itch Relief
- Recently launched Turfguard, a unique dressing for soothing turf burn and protecting athletic wound
- Launching beauty and cosmetic brand, Lumagel, in 2H23
- Currently selling products exclusively online (low capital commitment) and partnered with MPG for potential retail distribution



NOW PARABEN-FREE



## SilverSeal® Anti-Microbial Data

- SilverSeal® study was published *SAGE Journals' Scars, Burns and Healing* publication. The results indicated that SilverSeal demonstrated statistically significant improvement of skin functionality, fewer negative symptoms, and a reduction of scar appearance relative to standard petroleum-based dressing.
- NEXGEL, Inc. completed the validation of the anti-microbial properties of the SilverSeal® product line.
- The X-Static Silver-impregnated, hydrogel-based product was found to be up to 99% effective in reducing common bacteria, fungus, and yeasts that can be evident in wounds after superficial skin injury.

## SilverSeal® Opportunity

*40 patient double-blinded study data will allow NEXGEL to make a scar reduction claim  
Data has been submitted for peer review and publication*

- SilverSeal® currently being sold for OTC wound care online- sales growing
- Supporting clinical data will allow us to make the claim that SilverSeal® reduces scarring
- The scar treatment market is expected to grow to \$45.0 billion by 2028<sup>2</sup>

12 Weeks – Treated  
With SilverSeal®<sup>1</sup>



12 Weeks –  
Treated With  
Petroleum<sup>1</sup>



1. "The Use of Silver impregnated hydrogel sheet in the management of foot and ankle incisions and wounds" by Stephen A. Brigido DPM FACFAS Section Chief- Foot and Ankle Reconstruction Director, Fellowship for Foot and Ankle Reconstruction Coordinated Health at Lehigh Valley Hospital

2. "Scar Treatment Market by Type, Product, Region, Global Industry Analysis, Market Size, Share, Growth, Trends, and Forecast 2021 to 2028" report by Fior Markets

## Acquisition of Kenkoderm Skincare Line in December 2023

*Expands health and wellness consumer product portfolio with complimentary line of alternative treatments for psoriasis*

- Kenkoderm, for TTM, is profitable and expected to be immediately accretive
- Synergies support optimization of marketing and supply chain operations to drive revenue growth and margins
- 6 SKUs sold primarily DTC with significant portion of revenue derived from subscription bundles
- NEXGEL will immediately implement its marketing strategies and open new distribution channels



## Capacity Expansion Underway to Fulfill Expected Growth

*12,000 square foot expansion of Texas facility to support expected growth in product demand in 2024 is underway*

- Expansion will support the expected growth in product demand from its strategic partnerships with AbbVie and STADA, as well as retail launch in '24
- Expected to be completed during Q2 of '24
- Funded by landlord with lease terms to be adjusted accordingly to reflect the increase in square footage
- New automation equipment has been purchased and will be financed

# Financial Overview



NASDAQ: NXGL

---

## Revenue Growth with Scalable Infrastructure

### Income Statement:

- Record 2023 third quarter revenue: \$1.22 million, +115% YOY
- \$2.3 million in revenue generated in Q3 and Q2 of '23, exceeded full year 2022 revenue
- Contract manufacturing +182% YOY / branded consumer products +54% YOY
- Gross profit margin of 28.2% as compared to gross loss in Q1 of '23 and 15% in Q2 of '23
- Net loss improvement to \$550,000 (\$95,000 of non-cash items) as compared to a loss of \$814,000 in Q1 '23 and \$642,000 in Q2 of '23

---



### Balance Sheet:

- \$3.3 million of cash as of September 30, 2023
- Sufficient working capital to execute operating plan, including R&D, and invest in accelerating growth plan through 2025



NASDAQ: NXGL

# Growth Trends



NASDAQ: NXGL

# Multiple Paths for Growth

Scalable platform, strong cash position, and low cash needs for B2B expansion and online product sales enable multiple shots on goal with **path to profitability in '24**

|                              | Market  | Strategy   | Timeline  |
|------------------------------|---|--|---|
| Medical Devices              | Multi-billion hospital market   | Licensing model to existing medical device manufacturers   | 2025  |
| Proprietary Branded Products | Large markets in OTC consumer and beauty & cosmetics                            | Leverage existing facility capacity to capture sales through Amazon.com and retail (summer of '24)   | Growth: Led by hero product, SilverSeal, and new products with Kenkoderm  |
| White/Custom Label           | Low margin B2B projects, opportunity for co-development deals in the future     | Leverage existing facility capacity to provide line extensions for white label customers; co-develop products with partners for potential new products with IP | Ongoing effort to grow white label customers, while continuing to explore custom label deals  |
| Contract Manufacturing       | Converting and packaging finished goods, both new and existing NEXGEL customers | Benefits should increase once planned expansion, installation and validation of the new equipment is complete  | Already contributing materially to top line growth while benefiting bottom line as large growth opportunities with AbbVie and STADA come online |



NASDAQ: NXGL

# Contact Us

Investor Relations:  
KCSA Strategic Communications  
Valter Pinto, Managing Director  
[NEXGEL@KCSA.com](mailto:NEXGEL@KCSA.com)



NASDAQ: NXGL